Literature DB >> 11063130

Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues.

A Kálnay1, I Pályi, B Vincze, R Mihalik, I Mezõ, J Pató, J Seprõdi, S Lovas, R F Murphy.   

Abstract

The effect of various GnRH analogues, and their conjugates on proliferation, clonogenicity and cell cycle phase distribution of MCF-7 and Ishikawa human cancer cell lines was studied. GnRH-III, a sea lamprey GnRH analogue reduced cell proliferation by 35% and clonogenicity by 55%. Structural modifications either decreased, or did not alter biological activity. Conjugation of GnRH analogues including MI-1544, MI-1892, and GnRH-III with poly(N-vinylpyrrolidone-co-maleic acid) (P) through a tetrapeptide spacer GFLG(X) substantially increased the inhibitory effect of the GnRH analogues. The conjugate P-X-GnRH-III induced significant accumulation of cells in the G2/M phase; from 8% to 15.6% at 24 h and 9.8% to 15% at 48 h. It was concluded that conjugation of various GnRH analogues substantially enhanced their antiproliferative activity, strongly reduced cell clonogenicity and retarded cell progression through the cell division cycle at the G2/M phase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063130      PMCID: PMC6496190          DOI: 10.1046/j.1365-2184.2000.00180.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  19 in total

1.  Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.

Authors:  I Mezö; S Lovas; I Pályi; B Vincze; A Kálnay; G Turi; Z Vadász; J Seprödi; M Idei; G Tóth; E Gulyás; F Otvös; M Mák; J E Horváth; I Teplán; R F Murphy
Journal:  J Med Chem       Date:  1997-10-10       Impact factor: 7.446

Review 2.  LH-RH antagonists: state of the art and future perspectives.

Authors:  G F Weinbauer; E Nieschlag
Journal:  Recent Results Cancer Res       Date:  1992

3.  Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity.

Authors:  I Mezô; J Seprôdi; B Vincze; I Pályi; G Kéri; Z Vadász; G Tóth; M Kovács; M Koppán; J E Horváth; A Kálnay; I Teplán
Journal:  Biomed Pept Proteins Nucleic Acids       Date:  1996

4.  Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.

Authors:  M A Blankenstein; M S Henkelman; J G Klijn
Journal:  Eur J Cancer Clin Oncol       Date:  1985-12

5.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

Authors:  I Pályi; B Vincze; S Lovas; I Mezö; J Pató; A Kálnay; G Turi; D Gaál; R Mihalik; I Péter; I Teplán; R F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.

Authors:  B Vincze; I Pályi; D Gaál; J Pató; M Móra; I Mezõ; I Teplán; J Seprõdi
Journal:  Cancer Detect Prev       Date:  1996

7.  Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis.

Authors:  D Kleinman; A Douvdevani; A V Schally; J Levy; Y Sharoni
Journal:  Am J Obstet Gynecol       Date:  1994-01       Impact factor: 8.661

8.  Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium.

Authors:  M A Thompson; M D Adelson; L M Kaufman
Journal:  J Clin Endocrinol Metab       Date:  1991-05       Impact factor: 5.958

9.  Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  D Kleinman; C T Roberts; D LeRoith; A V Schally; J Levy; Y Sharoni
Journal:  Regul Pept       Date:  1993-10-20

10.  Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle.

Authors:  P Mullen; W N Scott; W R Miller
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.